Immunome (IMNM) Stock Price, News & Analysis

Company Overview

Immunome, Inc. (NASDAQ:IMNM) is a clinical‐stage biopharmaceutical company that specializes in the discovery and development of fully human therapeutic antibodies derived from naturally occurring immune repertoires. Utilizing its proprietary immune repertoire mining platform, the company captures and analyzes the diversity of antibodies produced by individuals who have successfully fought off disease, allowing it to identify potent, high-affinity candidates for a range of therapeutic indications. Based in Pittsburgh, Pennsylvania, Immunome’s technology is designed to accelerate antibody discovery while ensuring favorable safety and efficacy profiles.

The company’s pipeline spans oncology, infectious disease, and autoimmune disorders. By mining immunological memory, Immunome generates novel lead antibodies that can be advanced rapidly into preclinical and clinical development. Key therapeutic areas include B‐cell malignancies and emerging viral threats, with several programs currently in preclinical stages and at least one candidate approaching early‐phase clinical trials. In addition to internal development, Immunome partners with larger pharmaceutical firms and academic institutions to leverage its platform for antibody discovery across multiple disease targets.

Founded in 2016 as an offshoot of pioneering immunology research at the University of Pittsburgh, Immunome has grown under leadership with deep experience in drug development and translational science. The executive team is led by CEO David Humphreys, whose background includes senior roles in oncology research and biotech operations. The company’s scientific advisory board features leading immunologists and clinicians who guide target selection and strategic collaboration efforts.

While headquartered in the United States, Immunome maintains a global outlook, engaging in research collaborations and licensing discussions with partners in Europe and Asia. Its discovery platform can be applied across diverse therapeutic areas, positioning the company to address unmet medical needs worldwide. As Immunome advances its antibody candidates through the clinic, it aims to establish itself as a leader in next‐generation biologics derived from the human immune system.

Key Stats

• Today's Range: $8.60 to $8.91
• 50-Day Range: $7.43 to $9.79
• 52-Week Range: $5.15 to $16.81
• Volume: 231,449 shs
• Average Volume: 894,909 shs
• Market Capitalization: $766.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.33
• Consensus Rating: Buy

Immunome Stock Analysis - MarketRank™

Immunome scored higher than 40% of companies evaluated by MarketBeat, and ranked 509th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immunome has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunome is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunome is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunome has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.30% of the float of Immunome has been sold short.

Short Interest Ratio / Days to Cover

Immunome has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunome has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunome does not currently pay a dividend.

Dividend Growth

Immunome does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.30% of the float of Immunome has been sold short.

Short Interest Ratio / Days to Cover

Immunome has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunome has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Immunome this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

1 people have added Immunome to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.60% of the stock of Immunome is held by insiders.

Percentage Held by Institutions

44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMNM Stock Analysis - Frequently Asked Questions

How have IMNM shares performed this year?

Immunome's stock was trading at $10.62 at the beginning of the year. Since then, IMNM shares have decreased by 16.3% and is now trading at $8.89.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The business had revenue of $2.93 million for the quarter, compared to analysts' expectations of $0.46 million. Immunome had a negative trailing twelve-month return on equity of 71.65% and a negative net margin of 1,875.21%.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunome own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMNM
• CIK: 1472012
• Web: immunome.com
• Phone: 610-321-3700
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immunome: $23.33
• High Price Target: $30.00
• Low Price Target: $20.00
• Potential Upside/Downside: +162.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$292.96 million
• Net Margins: -1,875.21%
• Pretax Margin: -1,875.21%
• Return on Equity: -71.65%
• Return on Assets: -60.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.49
• Quick Ratio: 10.49

Sales & Book Value

• Annual Sales: $9.04 million
• Price / Sales: 85.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.27 per share
• Price / Book: 3.92

Miscellaneous

• Outstanding Shares: 87,010,000
• Free Float: 79,529,000
• Market Cap: $773.52 million
• Optionable: Optionable
• Beta: 1.92